Sequenom Inc (SQNM): Den Boom Dirk Van , CEO of Sequenom Inc purchased 40,000 shares on Jun 8, 2016. The Insider buying transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.09 per share for a total value of $43,600.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 12, 2016, Daniel S Md Grosu (SVP & CMO) purchased 30,000 shares at $1.11 per share price.On May 6, 2016, Carolyn Beaver (CFO) purchased 30,000 shares at $1.13 per share price.Also, On May 6, 2016, Jeffrey D Linton (Sr VP, GC & Secretary) purchased 10,000 shares at $1.15 per share price.On May 6, 2016, Den Boom Dirk Van (CEO) purchased 30,000 shares at $1.13 per share price.
Sequenom: On Tuesday, Jun 7, 2016 heightened volatility was witnessed in Sequenom which led to swings in the share price. The shares opened for trading at $1.08 and hit $1.17 on the upside , eventually ending the session at $1.12, with a gain of 1.82% or 0.02 points. The heightened volatility saw the trading volume jump to 9,41,491 shares. The 52-week high of the share price is $3.47 and the company has a market cap of $134 M . The 52-week low of the share price is at $0.9153.
Sequenom Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Company’s diagnostic services are provided through its wholly owned subsidiary Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in and by Sequenom Laboratories as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of and reimbursement for its prenatal LDTs and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories’ test offerings in the prenatal market include MaterniT21 PLUS LDT HerediT CF LDT SensiGene RhD LDT VisibiliT LDT and Test Send-out Agreements.